Related Experiment Video
Updated: Dec 7, 2025
09:44
Evaluation of Hepatic Glucose Production in a Polycystic Ovary Syndrome Mouse Model
Published on: March 5, 2022
3.2K
Exenatide, Metformin, or Both for Prediabetes in PCOS: A Randomized, Open-label, Parallel-group Controlled Study
Tao Tao1, Yi Zhang1, Yu-Chen Zhu1
1Department of Endocrinology and Metabolism, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
The Journal of Clinical Endocrinology and Metabolism
|September 30, 2020
Summary
Exenatide (EX) or combination therapy (EX plus metformin) significantly improved prediabetes remission rates in polycystic ovary syndrome (PCOS) patients compared to metformin alone. These findings highlight effective strategies for diabetes prevention in PCOS.
Area of Science:
- Endocrinology
- Metabolic Disorders
- Reproductive Medicine
Background:
- Polycystic ovary syndrome (PCOS) is frequently associated with prediabetes, increasing diabetes risk.
- Optimal pharmacotherapy for diabetes prevention in PCOS remains undefined.
- Prediabetes affects up to 40% of PCOS patients.
Purpose of the Study:
- To compare the clinical efficacy of exenatide (EX), metformin (MET), and combination therapy (COM) for prediabetes in patients with PCOS.
- To evaluate the impact of these treatments on metabolic and hormonal parameters.
- To assess the sustained remission rate of prediabetes.
Main Methods:
- A randomized, open-label, parallel-group controlled trial was conducted.
- 150 patients with PCOS and prediabetes were enrolled.
- Treatments included daily EX (10-20μg), MET (1500-2000 mg), or COM for 12 weeks, followed by a 12-week washout period.
Main Results:
- The overall sustained prediabetes remission rate was 50.7%.
- Combination therapy (64%) and EX monotherapy (56%) showed significantly higher remission rates than MET monotherapy (32%).
- EX demonstrated superior suppression of postprandial glucose and enhanced insulin secretion.
Conclusions:
- Exenatide and combination therapy are more effective than metformin monotherapy for achieving prediabetes remission in PCOS patients.
- Improved postprandial insulin secretion is a key mechanism for enhanced remission rates.
- These findings offer improved pharmacotherapy options for diabetes prevention in PCOS.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
500
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
500
01:23Dipeptidyl Peptidase 4 Inhibitors
428
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
428
01:24Glucagon-like Receptor Agonists
672
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
672
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
434
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
434
01:06Oral Hypoglycemic Agents: Glinides
467
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
467
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
134
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
134